Purpose: To investigate whether increased fluctuation of intraocular pressure (IOP) is an independent factor for glaucoma progression.
Elevated intraocular pressure (IOP) is an indisputable risk factor for glaucoma [1] [2] [3] and glaucoma progression. 4 As is well known, IOP fluctuation is proportional to IOP levels. 5, 6 Diurnal IOP fluctuation has been reported to be a risk factor, independent of IOP level, for development of glaucoma 7 or glaucoma progression, 8, 9 but these studies compared IOP measurements at different times, for example, baseline IOP fluctuation versus follow-up IOP levels, or before versus after a glaucoma intervention. Other reports studying various IOP parameters, measured during the same period and under the same conditions, have been unable to show that large IOP fluctuation is an independent risk for glaucoma 10 or glaucoma progression. 11 However, results from the Advanced Glaucoma Intervention Study (AGIS) 12 indicated that a larger long-term IOP fluctuation at follow-up, 13 defined as intervisit fluctuations of IOP, was associated with visual field progression. Mean follow-up IOP was not a significant risk factor when included in the same multivariate analysis. These analyses, however, also included IOP values after progression, which might have affected the results.
The role of IOP fluctuation as an independent predictive factor for glaucoma or glaucoma progression thus remains in doubt. Results from earlier studies are conflicting, and research designs perhaps were not always optimal. More studies investigating the independent effect of IOP fluctuation are needed to resolve this question.
The aim of this study was to examine the role of IOP fluctuation as an independent factor for glaucoma progression among patients included in the Early Manifest Glaucoma Trial (EMGT). 14 The EMGT is a randomized, controlled clinical trial designed to compare the effect of IOP reduction with treatment, versus no treatment, on glaucoma progression. The study population consisted of glaucoma patients, mainly (85%) identified by a large population screening, 15 who have been followed up for up to 11 years.
Patients and Methods

Overview
The EMGT design and methods have been described in detail elsewhere 15 and are here summarized. Patients with newly detected, previously untreated glaucoma, including primary openangle glaucoma, normal-tension glaucoma, and exfoliation glaucoma, were recruited. Eligible patients were between 50 and 80 years of age with reproducible glaucomatous visual field loss in at least 1 eye, but no advanced visual field loss, that is, mean deviation values better than Ϫ16 decibels, visual acuity equal to or better than 0.5 (corresponding to 20/40), mean IOP less than 31 mmHg, or any IOP less than 35 mmHg. The study was conducted according to the tenets of the Declaration of Helsinki. All patients gave informed consent, and the Ethics Committee of Lund University, Sweden, and the Committee on Research involving Human Subjects at the State University of New York at Stony Brook approved the study. Eligible patients were randomized evenly to treatment and no initial treatment. All eyes randomized to treatment received a full 360°trabeculoplasty plus betaxolol eye drops at a dosage of 5 mg/ml twice daily. All patients stayed in their allocation arm unless significant progression occurred. If IOP in treated eyes exceeded 25 mmHg at 2 consecutive follow-up visits or 35 mmHg in control eyes, latanoprost eye drops at a dose of 50 g/ml were added once daily.
Study Visit
After inclusion, patients were observed every 3 months for up to 11 years. The study visits included IOP measurements with the Goldmann applanation tonometer, used by technicians masked to study group and to earlier IOP values. Perimetry was performed with the Humphrey Field Analyzer using the Full-Threshold 30-2 program (Carl Zeiss Meditec, Inc., Dublin, CA). Patients also underwent best-corrected visual acuity measurements and a comprehensive eye examination, including ophthalmoscopy, with fundus photography every 6 months.
Glaucoma Progression and Unit of Analysis
This report is based on study data obtained up to March 31, 2004. Glaucoma progression was defined as worsening of visual fields according to a predetermined criterion, that is, at least 3 identical points showing significant deterioration in glaucoma change probability maps, based on change in pattern deviation values, at 3 consecutive visits. 15 This criterion has been shown to be sensitive to small visual field changes and to be able to measure deterioration in 12 to 15 steps from normal to almost blind, 16 while avoiding cataract-induced effects. During the first 9 years of the study, glaucoma progression also was identified by worsening of the disc, as assessed independently by 2 certified masked readers at the Optic Disc Reading Center. The EMGT progression is patient based and occurs when at least 1 eligible eye meets progression criteria. For patients with 1 eye eligible, only that eye was considered; for patients with 2 eligible eyes (n ϭ 61; 24%), analyses were based on the eye that progressed first. A similar approach was used in the analyses for this report, which also were patient based, following methods described and evaluated in a previous EMGT publication. 4 When a patient had 2 eligible eyes, data from the eye that progressed first were used; if neither eye progressed (or both progressed at the same time), data from the worse of the 2 baseline measurements (i.e., IOP and mean deviation) were included.
Intraocular Pressure
Analyses included all IOP measurements from 3 months (the first study visit after assignment to treatment or no initial treatment) to time of progression or last follow-up visit. Baseline IOP is not included because of the IOP changes in the treated group after randomization. The main variables of interest were the mean of the IOP at all applicable visits and the IOP fluctuation, defined as the standard deviation of IOP at these visits.
Statistical Analyses
We initially examined the IOP data in univariate analyses. Relationships between 2 continuous variables, that is, IOP fluctuation and time to progression, were evaluated first through correlation coefficients. The change in IOP for a patient was measured by the slope, which was obtained from regressing IOP measurements of that patient on time. The IOP slopes represent annual rates of IOP change. Summary statistics were used to describe the distribution of IOP slopes. Cox regression with time-dependent variables was used to evaluate the association between IOP fluctuation and time to progression, both with and without IOP mean in the models. These analyses also controlled for factors previously found relevant for progression. 4 The time-dependent Cox model is logh͑t͒ ϭ ␣͑t͒ ϩ ␤ 1 x 1 ͑t͒ ϩ ␤ 2 x 2 ͑t͒ ϩ ␤ 3 x 3 ͑t͒ ϩ ␤ 4 x 4 ͑t͒ ϩ ..., where h(t) is the hazard rate at time t; the time-dependent variable x 1 (t) is the standard deviation of IOP measurements from the 3-month visit to time t; the time-dependent variable x 2 (t) is the mean of IOP measurements from the 3-month visit to time t; and x 3 , x 4 , and so forth are values of other factors, for example, age group at baseline and exfoliation status. This model indicates that for each patient, the hazard for progression at time t depends on the value of the IOP mean and the IOP fluctuation at prior visits and on the values of additional variables previously found to be related to progression, for example, age and exfoliation status. 4 The partial maximum likelihood method was used to estimate the ␤ i values, which represent the change in the log hazard ratio (HR) resulting from unit change in risk factor x i (t) or x i . The Wald chi-square test was performed to test the association of IOP fluctuation and other factors with progression. The analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC).
Results
At data closure on March 31, 2004, the median follow-up time was 8 years (range, 0.1-11.1 years). Data from all 255 patients originally enrolled in the EMGT were included in the current analyses. Sixty-eight percent of the patients had progressed, with 59% of treated and 76% of control patients progressing. All patients in the control group remained untreated until reaching the outcome of glaucoma progression. The mean follow-up IOP was 19.5 mmHg for those who progressed and 16.5 mmHg for those who did not.
The corresponding values for mean follow-up IOP fluctuation (standard deviation) were 2.02 mmHg versus 1.78 mmHg, respectively. Intraocular pressure was very stable over time. Most patients had a flat IOP slope; 59% (125/254) were within Ϯ0.5 mmHg/year, and 92% (234/254) were within Ϯ3 mmHg/year (results are based on 254 patients because 1 patient had insufficient follow-up IOP values). Table 1 Table 2 presents analyses based on time-dependent variables. When jointly considering IOP mean and IOP fluctuation in the same model, results indicate that IOP mean was a significant risk factor for progression, with an 11% increase in the HR for every 1 mmHg higher. The IOP fluctuation, however, was not significantly related to progression; the HR was 1.00 per 1 mmHg, with 95% confidence limits ranging from 0.8 to 1.2. When parallel analyses were performed for the treatment and control groups separately, similar results were found, as shown in Table 3 . Thus, IOP fluctuation had little influence on the HR in the presence of IOP mean. In contrast, the effects of mean IOP on progression were significant and consistent in both study groups (HR, ϳ1.11 in both groups; PϽ0.05), regardless of the presence of IOP fluctuation.
Discussion
Our results continue to support our earlier conclusions regarding the effect of the magnitude of IOP on glaucoma progression, 4,14 and we were unable to demonstrate any effect of increased IOP fluctuation on glaucoma progression. In fact, our results yielded no significant relationship between higher IOP fluctuation and glaucoma progression.
Just as in the AGIS report, 13 we used the standard deviation of follow-up IOP measurements as a surrogate for IOP fluctuation, because no diurnal tension curves were obtained. Just as in the AGIS report, we used the same database for calculating mean IOP level and IOP fluctuation, unlike some previous studies where IOP fluctuation was measured at baseline and mean IOP level at follow-up visits, or before or after a possible intervention. 8, 9 Thus, both the AGIS and EMGT studied the concurrent independent effects of IOP fluctuation and mean IOP on progression, but revealed opposite results. The AGIS indicated that IOP fluctuation was an independent and stronger factor for glaucoma progression than mean IOP level, which was in contrast to the conclusion previously reported by the AGIS investigators. 5 In the EMGT, however, mean IOP level remained the strongest risk factor for glaucoma progression, even when including IOP fluctuation as a risk factor.
At first glance, these contradictory results seem difficult to interpret. However, the different types of patient selection, intervention, and approach to analyses may provide at least a partial explanation of some of the difference. In the AGIS, only patients with uncontrolled maximum acceptable therapy were included. Patients with an IOP lower than 18 mmHg were not eligible; 95% of all included patients had IOPs higher than 20 mmHg, and 74% had an IOP of 23 mmHg or higher. 12 The main evaluation of IOP fluctuation was based on only 68% of these AGIS participants (64% of AGIS eyes), because patients had to meet specific criteria related to visual field scores, reliability, and length of followup. The results based on this subset may not have been consistent in each AGIS intervention arm, which was a significant or near-significant variable in some models. The EMGT results presented here are based on all study patients, with comparable results in each study group.
In the EMGT, only untreated patients with newly detected glaucoma were eligible, and they were recruited largely via a population-based screening among specific age groups. There was no lower IOP limit for inclusion, but patients with any IOP of more than 35 mmHg or a mean IOP of greater than 30 mmHg were excluded. At baseline, untreated IOP was lower than 20 mmHg in 45% of the patients. 15 Therefore, most EMGT patients were newly identified from the general population, whereas those included in AGIS were highly selected, that is, patients with more advanced glaucoma and uncontrolled IOP at maximum therapy. Also, while most AGIS patients had a high IOP at baseline and all were treated, the EMGT patients had lower IOPs at baseline and this study included a treatment and a control arm.
At follow-up, patients included in the AGIS analysis had lower mean IOP, and higher IOP fluctuations, than EMGT patients. This difference is likely the result of the more aggressive treatment applied in the AGIS. The mean follow-up IOP in the AGIS was 15.4 mmHg among the patients who progressed and 14.5 mmHg among those who did not; the mean IOP fluctuation was 4.0 and 3.4 mmHg, respectively. In the EMGT, mean follow-up IOP was 19.5 mmHg and 16.5 mmHg among the progressing and nonprogressing patients, respectively, and IOP was very stable over time. The mean IOP fluctuation among those progressing was 2.0 mmHg and was 1.8 mmHg among the not progressing patients. Only 10.0% had intervisit fluctuations larger than 3 mmHg, with a maximum of 5.0 mmHg. This IOP stability could limit evaluations of the independent role of IOP fluctuation on glaucoma progression, because it does not provide a wide range of individual fluctuations.
An important strength of EMGT is that treatment remained unchanged during the period analyzed, that is, as long as progression did not occur. Therefore, progression or suspicion of progression did not lead to biases caused, for example, by more intense IOP-lowering treatment in progressing eyes. Our time-dependent analyses considered factors only up to the time of progression. As such, they did not include postprogression IOP values, which would be affected by treatment and thus unavoidably would result in higher IOP fluctuation. In the AGIS, eyes were assigned randomly to 1 of 2 surgical intervention sequences. If the first intervention was a failure, a second intervention was offered, and a third was offered when the second failed. Failure was defined by amount of visual field loss, by deterioration of disc rim, and also by magnitude and duration of IOP elevation. Although the number of surgical glaucoma interventions was included in the multivariate analysis to attempt correcting this bias, one cannot eliminate the possibility that treatment-induced IOP changes affected the results by increasing IOP fluctuation. It seems likely that progressing patients were more likely to receive newer, more potent topical medication, and such changes of therapy would not be corrected by the statistical analyses. We also considered the possible effects of other differences between the studies, for example, the use of different progression criteria. The AGIS applied pointwise linear regression analyses of threshold sensitivities, which are more sensitive to increasing media opacities than the EMGT progression criterion. 17 Filtering surgery often leads to progressive cataract, which in turn leads to a slow and monotonic worsening of threshold values. Therefore, it is reasonable to assume that the authors' visual field analysis resulted in more false-positive progression values in filtered than in nonfiltered eyes, thus leading to an apparent link between IOP change and progression. Also, because the patients included in the EMGT were newly diagnosed and had mostly mild to moderate glaucomatous visual field loss, our findings may not be applicable to patients with advanced glaucoma, as in the AGIS. By using Cox time-dependent analyses, we took time to progression into account. Time to progression was not considered in the AGIS analysis, which also may explain some of the difference.
In summary, we were unable to confirm earlier reports stating that IOP fluctuation is an independent risk for glaucoma progression. Instead, the current findings confirm our earlier results, that is, that elevated IOP level is a strong risk factor for glaucoma progression. Our con-clusion is based on data from previously undiagnosed and untreated glaucoma patients, found by a population screening. Therefore, we believe that our conclusion would be more applicable to a general glaucoma population, and not to highly selected subgroups.
